38 results about "Immunogenic cell death" patented technology

The present invention provides an immunomodulator for use in the treatment and / or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.

The invention provides a pharmaceutical composition for mild photothermal therapy of tumors as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is composed of a dual-targeting amphiphilic glucan derivative carrier, a material (PTA) with photo-thermal conversion performance and an autophagy inhibitor. The dual-targeting amphiphilic glucan derivative carrier can be self-assembled in water to form nano-micelles, and is physically loaded with PTA and an autophagy inhibitor for tumor photothermal therapy. The preparation is mainly characterized in that: 1) the preparation has active dual-targeting capability of tumor cells and tumor-related fibroblasts, and can efficiently enter the cells through the action of receptor ligands, so that the transfer efficiency of the preparation is improved; 2) under the irradiation of 808nm laser, PTA absorbs light energy and efficiently converts the light energy into heat, and the autophagy inhibitor inhibits the autophagy behavior of tumor cells and sensibilizes photo-thermal, so that an excellent mild photo-thermal treatment effect is realized, and the physical barrier of a tumor matrix can be weakened; tumor photothermal can further induce tumor cells to generate immunogenic cell death, generated tumor fragments can further activate an immune system, and the tumor photothermal treatment effect is greatly improved.

The invention discloses a new medicinal application of effective components and derivatives in Glycyrrhiza uralensis. The effective components and derivatives in Glycyrrhiza uralensis include liquiritin, glycyrrhizin, glycyrrhetinic acid, isoliquiritigenin, licochalcone A, glycyrrhizic acid and its derivative glycyrrhizic acid monoammonium salt, and the effective components and derivatives in Glycyrrhiza uralensis are used for preparing anticancer drugs. As that effective component in Glycyrrhiza uralensis and its derivative can induce tumor cells to produce immunogenic cell death. The invention provides a tumor treatment drug with definite curative effect, safety, convenience and wide sources, which can be combined with one or more pharmaceutically acceptable carriers or excipients to prepare pharmaceutical compositions or preparations of active components in licorice and derivatives thereof, it provides new drugs for tumor immunotherapy and is of great significance for improving tumor therapeutic effect and quality of life of patients. The effective components come from fruits, vegetables and medicinal materials, with small side effects, low cost and convenient popularization anduse.

There is provided a method of increasing progression-free lifetime or overall lifetime of a cancer patient, comprising: determining whether the cancer has an ambient microenvironment that facilitates immunomodulation; determining whether the chemotherapy regimen induces immunogenic cell death, and if both are so, administering an effective amount of a CDK4 / 6 inhibitor selected from Compound I, II, III, IV or V or a pharmaceutically acceptable salt thereof wherein the CDK4 / 6 inhibitor is administered prior to administration of chemotherapy or optionally prior to and concurrently with chemotherapy; and wherein the increase in progression-free lifetime or overall lifetime is compared to progression-free lifetime or overall lifetime based on the administration of chemotherapy alone, said comparison being based on evidence available in documents or otherwise disclosed, comparisons during preclinical or clinical trials, or other means accepted by those skilled in the art.

Contemplated compositions and methods counteract evasive measures of a tumor by rendering access to the tumor microenvironment, tagging the tumor microenvironment with chemoattractant and / or cytokines, delivering or facilitating a cell-based therapy in the tumor microenvironment while providing inhibition of immune suppressor cells in the tumor microenvironment.

The invention provides a bovine serum albumin-tea polyphenol-molybdenum nanocomposite, which belongs to the field of nanomedicine. The complex is to dissolve bovine serum albumin in water, then add tea polyphenol aqueous solution and molybdenum source aqueous solution drop by drop, and then add sodium hydroxide aqueous solution drop by drop, adopt biomineralization method to react, and obtain bovine serum albumin-tea Polyphenol‑Molybdenum Nanocomposite. The invention also provides the application of the bovine serum albumin-tea polyphenol-molybdenum nanocomposite in the preparation of immunogenic cell death and tumor immunotherapy drugs induced by the treatment of cancer cells. The complex of the invention has good biocompatibility, good dispersibility in water, good ability of inducing immunogenic cell death of mouse cancer cells, and can be effectively applied in tumor immunotherapy.

Use of (pyrophosphato)platinum(II) or platinum(IV) complexes (“phosphaplatins”), especially 1,2-cyclohexanediamine(pyrophosphato) platinum(II), as immunogenic cell death (ICD) inducing agents and their combination with immune checkpoint protein inhibitors for treatment of cancers, and the mechanistic rationale for the methods thereof, are disclosed.

The invention provides application of an immunogenic cell death-related gene in survival prognosis and radiotherapy responsiveness of head and neck squamous carcinoma, and belongs to the technical field of disease prognosis and molecular biology. According to the application, the immunogenic cell death-related gene prognostic index (ICDRGPI) is constructed by screening the head and neck squamous carcinoma prognosis-related gene, and the ICDRGPI is proved to have a good prediction effect on the survival of head and neck squamous carcinoma patients; and the survival of the ICDRGPI is obviously different from that of the patients after radiotherapy, and the ICDRGPI can be used for prognosis prediction of the head and neck squamous carcinoma patients and can assist clinical radiotherapy decision-making, so that the application has good practical application value.